Trial Profile
A 12-week, double-blind, placebo-controlled, randomized, parallel group, multicenter, fixed dose study to evaluate the efficacy and safety of a 20 mg/d oral dose of KW-6002 (istradefylline) as treatment for Parkinson's disease in patients with motor response complications on levodopa/carbidopa therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs Istradefylline (Primary)
- Indications Parkinson's disease
- Focus Registrational; Therapeutic Use
- Sponsors Kyowa Kirin; Kyowa Kirin Pharmaceutical Development
- 16 Sep 2020 Results of pooled analysis from four trials presented at the 24th International Congress of Parkinson's Disease and Movement Disorders
- 16 Sep 2020 Results of pooled analysis from four pivotal trials presented at the 24th International Congress of Parkinson's Disease and Movement Disorders
- 26 May 2020 Results presented at the 6th Congress of the European Academy of Neurology